Drug intelligence / Profile preview

BFM-PO-001

Development stage: Preclinical
Lead developer: Baiya Phytopharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BFM-PO-001 is a plant-produced monoclonal antibody developed by Baiya Phytopharm using their proprietary PlantamAb™ platform. It is designed to target and neutralize Immunoglobulin E (IgE), a key mediator in the allergic response. By binding to circulating IgE, BFM-PO-001 prevents it from attaching to high-affinity receptors (FcεRI) on mast cells and basophils, thereby reducing the release of inflammatory mediators that trigger asthma symptoms. This drug is currently in development for the treatment of asthma and potentially other allergic conditions.

Other names: PlantamAb™ IgE antibody

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on BFM-PO-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BFM-PO-001.